Edition:
India

Profile: Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

23.82USD
1:30am IST
Change (% chg)

$0.76 (+3.30%)
Prev Close
$23.06
Open
$23.10
Day's High
$24.44
Day's Low
$23.10
Volume
100,709
Avg. Vol
112,072
52-wk High
$24.45
52-wk Low
$11.45

Apellis Pharmaceuticals, Inc., incorporated on September 25, 2009, is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2.

The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration. The Company’s Advance APL-2 (intravitreal administration) into Phase II clinical development in GA and Phase II clinical development in wet AMD. The Company is developing APL-2 as monotherapy for GA, administered by intravitreal injections. In its ongoing Phase II clinical trial of APL-2 in patients with GA, treatment with APL-2 resulted in a reduction in the rate of GA lesion growth at 12 months compared to sham. The Company plan to discuss Phase III program in GA with the FDA and to initiate Phase III clinical trials of APL-2 in GA. The Company also plan to initiate a Phase II proof-of-concept trial of APL-2 in patients with wet AMD to evaluate the safety of APL-2 when administered with anti-VEGF treatments and then to evaluate whether treatment with APL-2 may allow wet AMD patients to reduce their dependence on anti-VEGF treatments.

The Company’s advance APL-2 systemic administration is into Phase III clinical development in paroxysmal nocturnal hemoglobinuria (PNH).The Company is developing APL-2 as monotherapy for patients with PNH, administered by subcutaneous injection. The Company also conducting Phase 1b clinical trials of APL-2 in patients being treated with eculizumab and in treatment-nave patients and evaluating dosing regimens such as twice and once per week dosing. In these two Phases 1b trials in PNH, APL-2 treatment was associated with improvements in transfusion dependency, hemoglobin levels and other hematological indicators. The Company also plans to discuss Phase III program with the FDA and initiate a Phase III clinical trial in patients with PNH.

Company Address

Apellis Pharmaceuticals Inc

6400 Westwind Way Ste a
CRESTWOOD   KY   40014-6773
P: +1502.2414114
F: +1302.6555049

Company Web Links